Roivant lung disease drug meets mid-stage trial endpoints

Roivant Sciences announced its investigational drug for a serious lung disease met primary goals in a Phase 2 trial. The positive results suggest a potential new treatment mechanism, but regulatory and later-stage validation remain pending. This is a company-specific clinical milestone with no immediate macro-market implications.